Aryl and heteroaryl substituted pyridino derivatives GABA...

Details Aryl and heteroaryl substituted pyridino derivatives GABA... Aryl and heteroaryl substituted pyridino derivatives GABA...

2000-06-15

2001-10-02

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S300000, C514S314000, C514S340000, C514S341000, C546S113000, C546S114000, C546S176000, C546S272400, C546S272700

Reexamination Certificate

active

06297256

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to aryl and heteroaryl substituted pyridino derivatives and to compounds that bind to the benzodiazepine site of GABA
A
receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the treatment of central nervous system (CNS) diseases.
2. Description of the Related Art
The GABA
A
receptor superfamily represents one of the classes of receptors through which the major inhibitory neurotransmitter, &ggr;-aminobutyric acid, or GABA, acts. Widely, although unequally, distributed through the mammalian brain, GABA mediates many of its actions through a complex of proteins called the GABA
A
receptor, which causes alteration in chloride conductance and membrane polarization.
A number of cDNAs for GABA
A
receptor subunits have been characterized. To date at least 6&agr;, 3&bgr;, 3&ggr;, 1&egr;, 1&dgr; and 2&rgr; subunits have been identified. It is generally accepted that native GABA
A
receptors are typically composed of 2&agr;, 2&bgr;, and
1&ggr; subunits (Pritchett & Seeburg
Science
1989; 245:1389-1392 and Knight et. al.,
Recept. Channels
1998; 6:1-18). Evidence such as message distribution, genome localization and biochemical study results suggest that the major naturally occurring receptor combinations are &agr;
1
&bgr;
2
&ggr;
2
, &agr;
2
&bgr;
3
&ggr;
2
, &agr;
3
&bgr;
3
&ggr;
2
, and &agr;
5
&bgr;
3
&ggr;
2
(Mohler et. al. Neuroch. Res. 1995; 20(5): 631-636).
Benzodiazepines exert their pharmacological actions by interacting with the benzodiazepine binding sites associated with the GABA
A
receptor. In addition to the benzodiazepine site, the GABA
A
receptor contains sites of interaction for several other classes of drugs. These include a steroid binding site, a picrotoxin site, and the barbiturate site. The benzodiazepine site of the GABA
A
receptor is a distinct site on the receptor complex that does not overlap with the site of interaction for GABA or for other classes of drugs that bind to the receptor (see, e.g., Cooper, et al., The Biochemical Basis of Neuropharmacology, 6
th
ed., 1991, pp. 145-148, Oxford University Press, New York). Early electrophysiological studies indicated that a major action of the benzodiazepines was enhancement of GABAergic inhibition. Compounds that selectively bind to the benzodiazepine site and enhance the ability of GABA to open GABA
A
receptor channels are agonists of GABA receptors. Other compounds that interact with the same site but negatively modulate the action of GABA are called inverse agonists. Compounds belonging to a third class bind selectively to the benzodiazepine site and yet have little or no effect on GABA activity, but can block the action of GABA
A
receptor agonists or inverse agonists that act at this site. These compounds are referred to as antagonists.
The important allosteric modulatory effects of drugs acting at the benzodiazepine site were recognized early and the distribution of activities at different receptor subtypes has been an area of intense pharmacological discovery. Agonists that act at the benzodiazepine site are known to exhibit anxiolytic, sedative, and hypnotic effects, while compounds that act as inverse agonists at this site elicit anxiogenic, cognition enhancing, and proconvulsant effects. While benzodiazepines have a long history of pharmaceutical use as anxiolytics, these compounds often exhibit a number of unwanted side effects. These may include cognitive impairment, sedation, ataxia, potentiation of ethanol effects, and a tendency for tolerance and drug dependence.
GABA
A
selective ligands may also act to potentiate the effects of other CNS active compounds. For example, there is evidence that selective serotonin reuptake inhibitors (SSRIs) may show greater antidepressant activity when used in combination with GABA
A
selective ligands than when used alone.
A variety of 2-aryl-4-piperidinoquinoline derivatives have been reported. See U.S. Pat. Nos. 4,560,692 and 4,728,647.
SUMMARY OF THE INVENTION
This invention provides heteroaryl substituted piperidines that bind with high affinity and high selectivity to the benzodiazepine site of the GABA
A
receptor, including human GABA
A
receptors.
Thus, the invention provides novel compounds of Formula I (shown below), and pharmaceutical compositions comprising compounds of Formula I.
The invention further comprises methods of treating patients suffering from CNS disorders with a therapeutically effective amount of a compound of the invention. The patient may be a human or other mammal. Treatment of humans, domesticated companion animals (pet) or livestock animals suffering from CNS disorders with an effective amount of a compound of the invention is encompassed by the invention.
In a separate aspect, the invention provides a method of potentiating the actions of other CNS active compounds. This method comprises administering an effective amount of a compound of the invention with another CNS active compound.
Additionally this invention relates to the use of the compounds of the invention as probes for the localization of GABA
A
receptors in tissue sections.
Accordingly, a broad aspect of the invention is directed to compounds of Formula I:
wherein:
n is 0 or an integer of from 1-3;
X is nitrogen or CR′, where R′ is lower hydrocarbyl or hydrogen;
R is hydrogen, lower hydrocarbyl, hydroxy, lower alkoxy, hydroxyhydrocarbyl, aminohydrocarbyl, or mono or di(C
1
-C
6
hydrocarbyl)aminohydrocarbyl;
A and B are the same or different and represent hydrogen, or straight or branched chain lower hydrocarbyl having 1-6 carbon atoms;
R
A
and R
B
, together with the two carbon atoms to which they are attached, form a 5-7 membered aryl group, or a 5-7 membered saturated or unsaturated ring optionally containing 1 or 2 nitrogens, or a heteroaryl ring having 5-7 members and containing at least one nitrogen, wherein each ring may be optionally substituted with 1, 2, or 3 substituents independently selected from halogen, hydroxy, C
1
-C
6
alkyl, alkoxy, amino, or mono or di(C
1
-C
6
alkyl)amino;
W is aryl or heteroaryl, each of which may be mono-, di- or trisubstituted independently with halogen, hydroxy, (C
1
-C
6
)lower hydrocarbyl, (C
1
-C
6
)lower alkoxy, amino, or mono- or di(C
1
-C
6
)hydrocarbylamino.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds encompassed by the instant invention can be described by general Formula I set forth above or the pharmaceutically acceptable non-toxic salts thereof.
Preferred compounds of Formula I include those wherein:
n is 0 or an integer of from 1-3;
X is nitrogen or CR′, where R′ is lower alkyl or hydrogen;
R is hydrogen, lower alkyl, hydroxy, lower alkoxy, hydroxyalkyl, aminoalkyl, or mono or di(C
1
-C
6
alkyl)aminoalkyl;
A and B are the same or different and represent hydrogen, or C
1
-C
6
alkyl having 1-6 carbon atoms;
R
A
and R
B
, together with the two carbon atoms to which they are attached, form a 5-7 membered aryl group, or a 5-7 membered saturated or unsaturated ring optionally containing 1 or 2 nitrogens, or a heteroaryl ring having 5-7 members and containing at least one nitrogen, wherein each ring may be optionally substituted with 1, 2, or 3 substituents independently selected from halogen, hydroxy, C
1
-C
6
alkyl, alkoxy, amino, or mono or di(C
1
-C
6
alkyl)amino;
W is aryl or heteroaryl, each of which may be mono-, di- or trisubstituted independently with halogen, hydroxy, (C
1
-C
6
)lower alkyl, (C
1
-C
6
)lower alkoxy, amino, or mono- or di(C
1
-C
6
)alkylamino.
Preferred compounds of Formula I further include those where A and B are the same or different and represent hydrogen or methyl. Preferred compounds of Formula I include those where R
A
and R
B
, together with the two carbon atoms to which they are attached, form a benzo, thieno, pyridino, or pyrimidino group. Each of these groups may be optionally substituted with 1, 2, or 3 substituents independently selected from halogen, hydroxy, C
1
-C
6
alkyl, alkoxy, amino, or mono or di (

Affiliated with

Also associated with

Rating

Aryl and heteroaryl substituted pyridino derivatives GABA... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl and heteroaryl substituted pyridino derivatives GABA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl and heteroaryl substituted pyridino derivatives GABA... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2588778